The available evidence does not show that a daughter kept her father's final loving note before Alzheimer's disease took his speech. Alzheimer's is an irreversible, progressive brain disorder, but the 2018 Reddit post says only that the writer's mother found a note his father wrote before the disease. The note may still hold profound meaning for the family. Readers should separate that emotional meaning from details the original post does not confirm.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the original story establishes
- What "took his speech" can mean
- How families can preserve meaningful messages
- Can newer Alzheimer's drugs restore speech?
- Who should discuss these treatments?
What the original story establishes
Words such as "daughter," "keeps," and "final" create a precise family story. The source does not provide enough information to support those details.
It also offers no timeline showing when the note was written, whether later notes existed, or when speech difficulties developed. The careful account is narrower: a mother found something the poster's father had written before Alzheimer's.
What "took his speech" can mean
alzheimer's damages memory and thinking and can eventually interfere with communication and simple tasks. However, each person's progression differs. "Took his speech" can be a family's understandable description of severe communication loss.
It is not a standardized disease stage or a milestone that everyone reaches in the same way. Speech loss also should not be treated as proof that someone has nothing left to express. Families can continue offering attention, simple choices, familiar gestures, and enough time for a response.
How families can preserve meaningful messages
A note can preserve a person's wording, handwriting, humor, or affection after communication becomes difficult. Families can protect that context without turning uncertain memories into facts.
When possible, ask the person which letters, recordings, photographs, or messages they want saved. Avoid pressuring someone with dementia to recreate a note or explain details they cannot reliably recall.
- Photograph or scan both sides of the note.
- Record where it was found and who found it.
- Label an estimated date as an estimate.
- Store the original safely and keep a digital copy elsewhere.
- Write down what relatives know separately from what they assume.
Can newer Alzheimer's drugs restore speech?
No approved anti-amyloid treatment has been shown to restore speech already lost to Alzheimer's. Lecanemab, sold as Leqembi, and donanemab, sold as Kisunla, are intended to slow decline in certain people with early disease. In trials, lecanemab produced 27% relative slowing over 18 months, while donanemab produced 29% relative slowing at 76 weeks.
Both treatment groups still declined, so these percentages do not mean patients improved by 27% or 29% (the lecanemab trial in The New England Journal of Medicine; the FDA's Kisunla trial summary). Those results are group averages, not forecasts for an individual. They do not establish that treatment will preserve a particular ability, such as speaking or writing.
Who should discuss these treatments?
Both medicines should be started only during mild cognitive impairment or mild dementia caused by Alzheimer's, with amyloid pathology confirmed. They are not indicated as a way to reverse advanced communication loss (the current Leqembi label; the Kisunla label). Both can cause amyloid-related imaging abnormalities, or ARIA—brain swelling or bleeding visible on imaging.
Leqembi's label reports ARIA in 21% of treated participants versus 9% receiving placebo, with higher risk among people carrying two copies of the ApoE ε4 variant. MRI monitoring and an individual risk discussion are essential. Before treatment, ask who will confirm the disease stage and amyloid pathology, review MRI and genetic risk, and manage monitoring. People using Medicare can also review the CMS statement on anti-amyloid coverage and registry requirements before arranging treatment.
